<h4>Background</h4>Lazertinib is a third-generation tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR-TKI) that selectively inhibit common EGFR mutation and T790M mutation in non-small-cell lung cancer (NSCLC) patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.